Mark Wildgust

Oncology

Mark Wildgust, VP of global medical affairs, oncology, at Johnson & Johnson Innovative Medicine, discusses J&J’s ambition to get in front of cancer.

News

The FDA has named Dexcom as the first company to take part in its TEMPO pilot, which aims to bring digital health tech to patients more quickly.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.